The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

Merck, Qure.ai collaborate to expand lung cancer detection via AI

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Merck Global Health Innovation Fund has made a strategic investment into Qure.ai as part of its Series D round. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

UCLA researchers awarded $3.2M NIH grant to develop AI tool for more personalized liver cancer treatment

Jason Chiang and Kyung Sung of the Department of Radiological Sciences at the David Geffen School of Medicine at UCLA and the UCLA Health Jonsson Comprehensive Cancer Center have received a $3.2 million, five-year grant from NCI to develop an artificial intelligence-enhanced imaging platform designed to improve yttrium-90 (Y90) radioembolization planning for patients with liver cancer.
Clinical Roundup

USC comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions

A head-to-head comparison of five leading treatments for anaplastic lymphoma kinase-positive non-small cell lung cancer could help oncologists fine-tune first-line TKI selection beyond what’s been seen in clinical trials alone, according to a study conducted by a team of researchers from the Keck School of Medicine of USC, the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences and the USC Shaeffer Center for Health Policy & Economics have conducted.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account